Top

07-08-2017 | Ovarian cancer | Article

Cancer Genetic Counseling and Testing: Perspectives of Epithelial Ovarian Cancer Patients and Gynecologic Oncology Healthcare Providers

Journal: Journal of Genetic Counseling

Authors: Margaret I. Liang, Deanna H. Wong, Christine S. Walsh, Robin Farias-Eisner, Joshua G. Cohen

Abstract

Multi-gene panel testing has expanded the genetic information available to cancer patients. The objective was to assess provider behaviors and attitudes and patient knowledge and attitudes towards genetic counseling and testing. An online survey was distributed to Society of Gynecologic Oncology members and a written questionnaire was administered to patients diagnosed with epithelial ovarian cancer at a tertiary care referral center. Most of the 233 (18% response rate) provider respondents were gynecologic oncologists. Access to a genetic counselor was reported by 87% of providers and 55% deferred all testing to genetic counselors. Of 53 ovarian cancer patient respondents, two-thirds had previously seen a genetic counselor or undergone testing. Patients’ attitudes about genetic counseling and/or testing were favorable with respect to themselves (70–81%) and their family members (94%). Less than 25% of patients indicated worrying about health care discrimination, lack of privacy, or high cost. Seventy-seven percent of patients demonstrated a desire to obtain genetic information even if the results were not currently actionable, and 20% of providers stated they test for only those genes with guideline-supported actionable results. Provider practice differences were identified in screening and prevention strategies for patients with deleterious non-BRCA mutations and variants of uncertain significance. The variation in clinical interpretation of results associated with poorly defined cancer risks signals a need for more comprehensive training and guidelines to ensure access to evidence-based care.

Balmana, J., Digiovanni, L., Gaddam, P., Walsh, M. F., Joseph, V., Stadler, Z. K., Nathanson, K. L., et al. (2016). Conflicting interpretation of genetic variants and cancer risk by commercial laboratories as assessed by the prospective registry of multiplex testing. Journal of Clinical Oncology. doi:10.1200/JCO.2016.68.4316.

Bernhardt, B. (2014). Genetic counselors and the future of clinical genomics. Genome Medicine, 6, 49.CrossRefPubMedPubMedCentral

Bolton, K. L., Chenevix-Trench, G., Goh, C., Sadetzki, S., Ramus, S. J., Karlan, B. Y., Lambrechts, D., et al. (2012). Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA, 307, 382–390.CrossRefPubMedPubMedCentral

Casadei, S., Norquist, B. M., Walsh, T., Stray, S., Mandell, J. B., Lee, M. K., Stamatoyannopoulos, J. A., et al. (2011). Contribution of inherited mutations in the BRCA2-interacting protein PALB2 to familial breast cancer. Cancer Research, 71, 2222–2229.CrossRefPubMedPubMedCentral

Cass, I., Baldwin, R. L., Varkey, T., Moslehi, R., Narod, S. A., & Karlan, B. Y. (2003). Improved survival in women with BRCA-associated ovarian carcinoma. Cancer, 97, 2187–2195.CrossRefPubMed

Conrad, L. B., Ramirez, P. T., Burke, W., Naumann, R. W., Ring, K. L., Munsell, M. F., & Frumovitz, M. (2015). Role of minimally invasive surgery in gynecologic oncology: An updated survey of members of the Society of Gynecologic Oncology. International Journal of Gynecological Cancer, 25, 1121–1127.CrossRefPubMedPubMedCentral

Culver, J. O., Brinkerhoff, C. D., Clague, J., Yang, K., Singh, K. E., Sand, S. R., & Weitzel, J. N. (2013). Variants of uncertain significance in BRCA testing: Evaluation of surgical decisions, risk perception, and cancer distress. Clinical Genetics, 84, 464–472.CrossRefPubMedPubMedCentral

Daly, M.B., Pilarski, R., Berry, M., Buys, S.S., Farmer, M., Friedman, S., Garber, J.E., et al. (2016). NCCN clinical practice guidelines in oncology: genetic/familial high-risk assessment: breast and ovarian, version 2.2016. Fort Washington: National Comprehensive Cancer Network. Available at: https://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf.

Desmond, A., Kurian, A. W., Gabree, M., Mills, M. A., Anderson, M. J., Kobayashi, Y., Horick, N., et al. (2015). Clinical actionability of multigene panel testing for hereditary breast and ovarian cancer risk assessment. JAMA Oncology, 1, 943–951.CrossRefPubMed

Domchek, S. M., Friebel, T. M., Singer, C. F., Evans, D. G., Lynch, H. T., Isaacs, C., Garber, J. E., et al. (2010). Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA, 304, 967–975.CrossRefPubMedPubMedCentral

El-Sahwi, K. S., Illuzzi, J., Varughese, J., Carusillo, N., Ratner, E. S., Silasi, D. A., Azodi, M., et al. (2012). A survey of gynecologic oncologists regarding the end-of-life discussion: a pilot study. Gynecologic Oncology, 124, 471–473.CrossRefPubMed

Febrraro, T., Robison, K., Wilbur, J. S., Laprise, J., Bregar, A., Lopes, V., Legare, R., et al. (2015). Adherence patterns to National Comprehensive Cancer Network (NCCN) guidelines for referral to cancer genetic professionals. Gynecologic Oncology, 138, 109–114.CrossRef

Finch, A., Beiner, M., Lubinski, J., Lynch, H. T., Moller, P., Rosen, B., Murphy, J., et al. (2006). Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation. JAMA, 296, 185–192.CrossRefPubMed

George, R., Kovak, K., & Cox, S. (2015). Aligning policy to promote cascade genetic screening for prevention and early diagnosis of heritable diseases. Journal of Genetic Counseling, 24, 388–399.CrossRefPubMed

Hartmann, L. C., & Lindor, N. M. (2016). The role of risk-reducing surgery in hereditary breast and ovarian cancer. The New England Journal of Medicine, 374, 454–468.CrossRefPubMed

Howlader, N., Noone, A.M., Krapcho, M., Miller, D., Bishop, K., Altekruse, S.F., Kosary, C.L., et al. (2016). SEER cancer statistics review, 1975–2013, based on November 2015 SEER data submission, posted to the SEER website, April 2016. Bethesda: National Cancer Institute. Available at: http://seer.cancer.gov/csr/1975_2013/.

Iodice, S., Barile, M., Rotmensz, N., Feroce, I., Bonanni, B., Radice, P., Bernard, L., et al. (2010). Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: a meta-analysis. European Journal of Cancer, 46, 2275–2284.CrossRefPubMed

Knapke, S., Haidle, J. L., Nagy, R., & Pirzadeh-Miller, S. (2016). The current state of cancer genetic counseling access and availability. Genetics in Medicine, 18, 410–412.CrossRefPubMed

Lacour, R. A., Daniels, M. S., Westin, S. N., Meyer, L. A., Burke, C. C., Burns, K. A., Kurian, S., et al. (2008). What women with ovarian cancer think and know about genetic testing. Gynecologic Oncology, 111, 132–136.CrossRefPubMedPubMedCentral

Lancaster, J. M., Powell, C. B., Chen, L. M., Richardson, D. L., & Clinical Practice Committee, S. G. O. (2015). Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions. Gynecologic Oncology, 136, 3–7.CrossRefPubMed

Ledermann, J., Harter, P., Gourley, C., Friedlander, M., Vergote, I., et al. (2012). Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. The New England Journal of Medicine, 366, 1382–1392.CrossRefPubMed

Ledermann, J., Harter, P., Gourley, C., Friedlander, M., Vergote, I., Rustin, G., Scott, C. L., et al. (2014). Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. The Lancet Oncology, 15, 852–861.CrossRefPubMed

Loveday, C., Turnbull, C., Ramsay, E., Hughes, D., Ruark, E., Frankum, J. R., Bowden, G., et al. (2011). Germline mutations in RAD51D confer susceptibility to ovarian cancer. Nature Genetics, 43, 879–882.CrossRefPubMedPubMedCentral

Loveday, C., Turnbull, C., Ruark, E., Xicola, R. M., Ramsay, E., Hughes, D., Warren-Perry, M., et al. (2012). Germline RAD51C mutations confer susceptibility to ovarian cancer. Nature Genetics, 44, 475–476.CrossRefPubMed

Meyer, L. A., Anderson, M. E., Lacour, R. A., Suri, A., Daniels, M. S., Urbauer, D. L., Nogueras-Gonzalez, G. M., et al. (2010). Evaluating women with ovarian cancer for BRCA1 and BRCA2 mutations: missed opportunities. Obstetrics and Gynecology, 115, 945–952.CrossRefPubMedPubMedCentral

Morgan, R.J. Jr, Armstrong, D.K., Alvarez, R.D., Bakkum-Gamez, J.N., Behbakht, K., Chen, L.M., Copeland, L., et al. (2016). NCCN clinical practice guidelines in oncology: ovarian cancer including fallopian tube cancer and primary peritoneal cancer, version 1.2016. Fort Washington: National Comprehensive Cancer Network. Available at: https://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf.

Oei, A. L., Massuger, L. F., Bulten, J., Ligtenberg, M. J., Hoogerbrugge, N., & de Hullu, J. A. (2006). Surveillance of women at high risk for hereditary ovarian cancer is inefficient. British Journal of Cancer, 94, 814–819.CrossRefPubMedPubMedCentral

Petrucelli, N., Lazebnik, H. K. M., & Lazebnik. (2002). Clinical interpretation and recommendations for patients with a variant of uncertain significance in BRCA1 or BRCA2: a survey of genetic counseling practice. Genetic Testing, 6, 107–113.CrossRefPubMed

Plon, S. E., Cooper, H. P., Parks, B., Dhar, S. U., Kelly, P. A., Weinberg, A. D., Staggs, S., et al. (2011). Genetic testing and cancer risk management recommendations by physicians for at-risk relatives. Genetics in Medicine, 13, 148–154.CrossRefPubMedPubMedCentral

Rafnar, T., Gudbjartsson, E. F., Sulem, P., Jonasdottir, A., Sigurdsson, A., Jonasdottir, A., Besenbacher, S., et al. (2011). Mutations in BRIP1 confer high risk of ovarian cancer. Nature Genetics, 43, 1104–1107.CrossRefPubMed

Robson, M. E., Bradbury, A. R., Arun, B., Domchek, S. M., & Ford, J. M. (2015). American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility. Journal of Clinical Oncology, 33, 1–10.CrossRef

Siegel, R. L., Miller, K. D., & Jemal, A. (2016). Cancer statistics, 2016. CA: a Cancer Journal for Clinicians, 66, 7–30.

Tung, N., Domchek, S. M., Stadler, Z., Nathanson, K. L., Couch, F., Garber, J. E., Offit, K., et al. (2016). Counselling framework for moderate-penetrance cancer-susceptibility mutations. Nature Reviews. Clinical Oncology, 13, 581–588.CrossRefPubMedPubMedCentral

van der Velde, N. M., Mourits, M. J. E., Arts, H. G., de Vries, J., Leegte, B. K., Dijkhuis, G., Oosterwijk, J. C., et al. (2009). Time to stop ovarian cancer screening in BRCA1/2 mutation carriers? International Journal of Cancer, 124, 919–923.CrossRefPubMed

Walker, J. L., Powell, C. B., Chen, L. M., Carter, J., Bae Jump, V. L., Parker, L. P., Borowsky, M. E., et al. (2015). Society of Gynecologic Oncology recommendations for the prevention of ovarian cancer. Cancer, 121, 2108–2120.CrossRefPubMed

Walsh, C. S. (2015). Two decades beyond BRCA1/2: homologous recombination, hereditary cancer risk and a target for ovarian cancer therapy. Gynecologic Oncology, 137, 343–350.CrossRefPubMed

Walsh, T., Casadei, S., Lee, M. K., Pennil, C. C., Nord, A. S., Thornton, A. M., Roeb, W., et al. (2011). Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proceedings of the National Academy of Sciences of the United States of America, 108, 18032–18037.CrossRefPubMedPubMedCentral

Wang, G., Beattie, M. S., Ponce, N. A., & Phillips, K. A. (2011). Eligibility criteria in private and public coverage policies for BRCA genetic testing and genetic counseling. Genetics in Medicine, 13, 1045–1050.CrossRefPubMedPubMedCentral

Wright, J. D., Chen, L., Tergas, A. I., Accordino, M., Ananth, C. V., Neugut, A. I., & Hershman, D. L. (2016). Underuse of BRCA testing in patients with breast and ovarian cancer. American Journal of Obstetrics and Gynecology, 214, 761–763.CrossRefPubMed

Yang, D., Khan, S., Sun, Y., Hess, K., Shmulevich, I., Sood, A. K., & Zhang, W. (2011). Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA, 306, 1557–1565.CrossRefPubMedPubMedCentral

Medicine Matters Oncology

Abstract